1544 related articles for article (PubMed ID: 35113855)
1. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.
Yarmolinsky J; Díez-Obrero V; Richardson TG; Pigeyre M; Sjaarda J; Paré G; Walker VM; Vincent EE; Tan VY; Obón-Santacana M; Albanes D; Hampe J; Gsur A; Hampel H; Pai RK; Jenkins M; Gallinger S; Casey G; Zheng W; Amos CI; ; ; ; Smith GD; Martin RM; Moreno V
PLoS Med; 2022 Feb; 19(2):e1003897. PubMed ID: 35113855
[TBL] [Abstract][Full Text] [Related]
2. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
3. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
4. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
5. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
6. Exploring the causal relationship between antihypertensive drugs and glioblastoma by combining drug target Mendelian randomization study, eQTL colocalization, and single-cell RNA sequencing.
Zhao S; Xie Y; Ding X; Zheng C; Chen J; Zhao N; Ji Y; Wang Q; Liu Y; Cheng C
Environ Toxicol; 2024 Jun; 39(6):3425-3433. PubMed ID: 38450887
[TBL] [Abstract][Full Text] [Related]
7. Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study.
Ardissino M; Slob EAW; Rajasundaram S; Reddy RK; Woolf B; Girling J; Johnson MR; Ng FS; Gill D
BMC Med; 2022 Sep; 20(1):288. PubMed ID: 36064525
[TBL] [Abstract][Full Text] [Related]
8. Association of Antihypertensive Drug Target Genes With Psychiatric Disorders: A Mendelian Randomization Study.
Chauquet S; Zhu Z; O'Donovan MC; Walters JTR; Wray NR; Shah S
JAMA Psychiatry; 2021 Jun; 78(6):623-631. PubMed ID: 33688928
[TBL] [Abstract][Full Text] [Related]
9. The evolution of mendelian randomization for investigating drug effects.
Gill D; Burgess S
PLoS Med; 2022 Feb; 19(2):e1003898. PubMed ID: 35113864
[TBL] [Abstract][Full Text] [Related]
10. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.
Yarmolinsky J; Robinson JW; Mariosa D; Karhunen V; Huang J; Dimou N; Murphy N; Burrows K; Bouras E; Smith-Byrne K; Lewis SJ; Galesloot TE; Kiemeney LA; Vermeulen S; Martin P; Albanes D; Hou L; Newcomb PA; White E; Wolk A; Wu AH; Le Marchand L; Phipps AI; Buchanan DD; ; ; Zhao SS; Gill D; Chanock SJ; Purdue MP; Davey Smith G; Brennan P; Herzig KH; Järvelin MR; Amos CI; Hung RJ; Dehghan A; Johansson M; Gunter MJ; Tsilidis KK; Martin RM
EBioMedicine; 2024 Feb; 100():104991. PubMed ID: 38301482
[TBL] [Abstract][Full Text] [Related]
11. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study.
Morales Berstein F; McCartney DL; Lu AT; Tsilidis KK; Bouras E; Haycock P; Burrows K; Phipps AI; Buchanan DD; Cheng I; ; Martin RM; Davey Smith G; Relton CL; Horvath S; Marioni RE; Richardson TG; Richmond RC
Elife; 2022 Mar; 11():. PubMed ID: 35346416
[TBL] [Abstract][Full Text] [Related]
12. Genetically determined blood pressure, antihypertensive medications, and risk of intracranial aneurysms and aneurysmal subarachnoid hemorrhage: A Mendelian randomization study.
Liu H; Zuo H; Johanna O; Zhao R; Yang P; Chen W; Li Q; Lin X; Zhou Y; Liu J
Eur Stroke J; 2024 Mar; 9(1):244-250. PubMed ID: 37800876
[TBL] [Abstract][Full Text] [Related]
13. Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study.
Yuan S; Burgess S; Laffan M; Mason AM; Dichgans M; Gill D; Larsson SC
J Am Heart Assoc; 2021 Apr; 10(8):e019644. PubMed ID: 33834859
[TBL] [Abstract][Full Text] [Related]
14. Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.
Sun X; Ping J; Guo X; Long J; Cai Q; Shu XO; Shu X
Mol Carcinog; 2024 May; 63(5):849-858. PubMed ID: 38517045
[TBL] [Abstract][Full Text] [Related]
15. Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study.
Zhao JV; Liu F; Schooling CM; Li J; Gu D; Lu X
Diabetologia; 2022 Apr; 65(4):695-704. PubMed ID: 35080656
[TBL] [Abstract][Full Text] [Related]
16. Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study.
Wang Z; Lu J; Hu J
Liver Int; 2023 Jun; 43(6):1320-1331. PubMed ID: 37005366
[TBL] [Abstract][Full Text] [Related]
17. Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populations.
Fan B; Zhao JV
BMC Med; 2024 Jan; 22(1):6. PubMed ID: 38166843
[TBL] [Abstract][Full Text] [Related]
18. Genetically predicted blood pressure, antihypertensive drugs and risk of heart failure: a Mendelian randomization study.
Lian J; Shi X; Jia X; Fan J; Wang Y; Zhao Y; Yang Y
J Hypertens; 2023 Jan; 41(1):44-50. PubMed ID: 36129112
[TBL] [Abstract][Full Text] [Related]
19. Genetically proxied milk consumption and risk of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian randomization study.
Larsson SC; Mason AM; Kar S; Vithayathil M; Carter P; Baron JA; Michaëlsson K; Burgess S
BMC Med; 2020 Dec; 18(1):370. PubMed ID: 33261611
[TBL] [Abstract][Full Text] [Related]
20. Association between genetically proxied PCSK9 inhibition and systemic lupus erythematosus risk: A mendelian randomization study.
Ji X; Guo HY; Han M; Peng H; Yuan H
Int J Rheum Dis; 2024 Apr; 27(4):e15106. PubMed ID: 38568054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
